ARCT - Arcturus gains with positive views from Piper Sandler on COVID-19 booster

COVID-19 vaccine developer Arcturus Therapeutics (ARCT +10.6%) have outperformed rival shot makers on Tuesday after Piper Sandler issued positive remarks on the company’s messenger-RNA-based vaccine booster. Identified as LUNAR-COV19 vaccine candidates, Arcturus has three experimental vaccines, ARCT-021, ARCT-154, and ARCT-165, in its pipeline. The next-gen vaccine candidates, ARCT-154 and ARCT-165, are undergoing two current clinical studies as a booster vaccination series. In its latest 10-K filing, Arcturus (NASDAQ:ARCT) announced that a pharmaceutical company has agreed to fund up to $25 million to study a LUNAR-COV19 vaccine candidate as a booster. The disclosure prompted Piper Sandler analyst Yasmeen Rahimi to indicate “high conviction” on the company’s booster shot. She argues that the partner’s interest in the booster bodes well as Arcturus (ARCT) prepares to disclose data for ARCT-154. Read more on the upcoming milestones for the company, as outlined by its management last month.

For further details see:

Arcturus gains with positive views from Piper Sandler on COVID-19 booster